Objectives: The value of ventilation monitoring with end-tidal carbon dioxide (ETCO 2 ) to anticipate acute respiratory events during emergency department (ED) procedural sedation and analgesia (PSA) is unclear. The authors sought to determine if ETCO 2 monitoring would reveal findings indicating an acute respiratory event earlier than indicated by current monitoring practices.
P rocedural sedation and analgesia (PSA) is an integral part of emergency medicine practice. Current emergency department (ED) practice guidelines advocate routine assessment of patients during moderate or deep sedation with continuous oxygenation and hemodynamic monitoring. 1 A variety of patient assessment scales are also used, including the Ramsay scale and the modified postanesthesia recovery score. Ventilation monitoring by clinical observation is also routine during PSA; however, recent studies have questioned the sensitivity of this practice for early changes in respiratory status. 2, 3 In the operating room, end-tidal carbon dioxide (ETCO 2 ) monitoring is standard practice for ventilation monitoring and is the earliest indicator of airway compromise, including respiratory depression, apnea, and upper airway obstruction. In the setting of ED PSA, the utility of ETCO 2 monitoring is less clear, and no specialty organizations have advocated its routine use as an essential element for ED PSA practice. 1, [4] [5] [6] [7] [8] [9] [10] The primary goal of this study was to determine the ability of ETCO 2 monitoring during PSA to detect acute respiratory events before detection by current monitoring methods. We sought to assess the frequency of abnormal ETCO 2 findings during PSA and to define the relationship between observed ETCO 2 findings and acute respiratory events.
METHODS

Study Design
This investigation was a prospective observational case series with a convenience sample of ED patients undergoing PSA. The study was approved by the institutional review board for research on human subjects. Prospective informed consent was obtained.
Study Setting and Population
The study site is a 500-bed tertiary care hospital with an ED volume of 52,000 patients per year and approximately 250 PSA interventions per year. Emergency attending or resident physician personnel considered consecutive adult and pediatric ED patients for study enrollment at the time of the decision to perform PSA. Enrollment was conducted over a six-month period (May to October 2004). Patients were excluded from enrollment if unable to give informed consent or if there were no study investigators available.
Study Protocol
Procedural sedation and analgesia was performed in a fashion consistent with generally accepted guidelines, including monitoring continuous oxygen saturation (SpO 2 ), heart rate, cardiac rhythm, respiratory rate, and interval blood pressure.
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A study investigator who did not participate in patient care was present throughout each PSA encounter and recorded all study data and observations, assured the quality of SpO 2 and ETCO 2 waveform data, and assured the proper positioning of patient monitoring equipment. The study investigators were four emergency physicians, one attending physician and three resident physicians, who enrolled patients during ED clinical shifts. These investigators agreed on monitoring practices and procedures before beginning patient enrollment and intermittently met to assure that consistent enrollment practices were being maintained. The clinical team was blinded to study monitoring data, including ETCO 2 findings, throughout the PSA period.
Outcome Measures
Study measurements included a Ramsay score clinical assessment and patient monitoring data (SpO 2 , heart rate, respiratory rate, and ETCO 2 ) obtained via a multiparameter monitor (LIFEPAK 12 defibrillator/monitor series; Medtronic Emergency Response Systems, Redmond, WA). ETCO 2 monitoring was performed using a combined oral/nasal cannula for ETCO 2 measurement that simultaneously samples CO 2 and delivers low-flow oxygen. Administration of supplemental oxygen (2 L/min) during PSA was routine practice during the study period and a component of the institutional PSA policy.
The LIFEPAK 12 series Microstream technology quantitatively assesses expired CO 2 directly via an infrared light beam with a narrow wavelength of light that is projected through the exhaled gas sample. The intensity of the transmitted light is measured, with the light absorbed dependent on the concentration of CO 2 molecules in the sample.
The ETCO 2 data displayed to the study investigator included a continuous graphical display of the detected exhaled CO 2 waveform (capnography) and a continuous numerical display of measured CO 2 (capnometry). Recorded study monitoring data included a time and date signature for the data assessment, capnometric ETCO 2 value, respiratory rate, and SpO 2 . The LIFEPAK 12 software was not configured to record capnography waveform data. Study monitoring data were recorded every 30 seconds during PSA and were collected simultaneously with the clinical team monitoring. In addition to the 30-second interval monitoring data, data were captured at the following times: baseline observations before medication administration, administration of any medication (either sedative or analgesic), observed acute respiratory events, acute clinical interventions for respiratory events, and return to baseline.
We defined clinically important acute respiratory events and related clinical interventions to include one or more of the following: SpO 2 %92%; increases in the amount of supplemental oxygen provided in response to observed apnea, hypoventilation, or desaturation (e.g., increasing oxygen from 2 to 4 L or from low-flow cannula to high-flow facemask); use of bag-valve mask or oral/nasal airway for ventilatory assistance or apnea; repositioning or airway alignment maneuvers for ventilation or apnea; physical or verbal stimulation for depressed ventilation or apnea; and reversal agent administration. A change in ETCO 2 level R10 mm Hg from the presedation baseline and an intrasedation ETCO 2 level %30 mm Hg or R50 mm Hg were considered investigational acute respiratory events. 4, [6] [7] [8] [9] For observed acute respiratory events, the type and time of the acute respiratory events were entered into the monitor along with the clinical assessment and vital sign data at that time.
Data Analysis
Patient enrollment was planned for a one-year period of PSA encounters with a projected volume of 250 patients. The investigators anticipated an acute respiratory event occurrence rate of 15% based on a PSA database at this institution and the acute respiratory event definition used for the study protocol.
In response to concerns raised by the emergency physician faculty and the institutional review board for research on human subjects at the study site concerning the uncertain implication of PSA ETCO 2 findings, the investigators were required to institute an interim safety analysis for each 30-patient enrollment block. This analysis was performed by two study investigators and a research nurse who did not participate in the study. The institutional review board and physician staff identified a blinded study cessation point as investigative findings suggestive of periods of patient apnea or hypoventilation undetected by standard monitoring practices yet revealed with ETCO 2 continuous assessment.
Measurements are reported using descriptive statistics. Selected continuous variables are reported as median values with range. The software package used for data collection and analysis was SPSS 11.0 (SPSS Inc., Chicago, IL). Table 1 .
RESULTS
After review of two
30-patient enrollment blocks, it was determined that further use of ETCO 2 monitoring should proceed in a nonblinded fashion and the study was terminated. Fifty-nine patients with 60 PSA encounters were enrolled over the six-month period. One patient had two separate PSA encounters during a single ED visit (midazolam and fentanyl for transesophageal echocardiography, followed approximately one hour later with propofol for atrial fibrillation cardioversion). Patient demographic and clinical descriptors are shown in
ETCO 2 Findings
Abnormal ETCO 2 findings were documented in 36 of the 60 encounters (60%). For those patients with abnormal ETCO 2 levels, 32 patients had abnormally low levels and five patients had abnormally high levels (one patient had both a low and a high level during the PSA encounter). In 16 (44%) of these 36 encounters, there were no other acute respiratory events observed and no interventions by the clinical team. These abnormal ETCO 2 levels ranged from single, isolated abnormal ETCO 2 recordings to periods of multiple, prolonged abnormal ETCO 2 values for each patient.
Acute Respiratory Events
Investigators documented 20 acute respiratory events in the 60 PSA encounters (33%). A description of these patients and their acute respiratory events are displayed in Table 2 . An illustrative case of a patient with an acute respiratory event and associated monitoring data is shown in Figure 1 .
Seventeen patients (85%) with acute respiratory events demonstrated ETCO 2 findings indicative of hypoventilation or apnea. These abnormal ETCO 2 findings were documented before changes in SpO 2 or observed changes in respiratory rate in 14 patients (70%) with acute respiratory events. All adverse respiratory events resolved with the interventions documented in Table 2 .
DISCUSSION
Respiratory depression and airway obstruction have been cited as the primary cause of adverse events associated with PSA. 10 Current assessment of these parameters is by clinical observation, continuous pulse oximetry, and observed respiratory rate.
Clinical observation of the patient is known to be limited in its ability to detect respiratory depression and obstruction during PSA. 4, 10 Continuous pulse oximetry is also limited for detection of respiratory depression and obstruction, given the physiologic differences between oxygenation and ventilation. The practice of preoxygenation, via supplemental oxygen before and during PSA, may further delay the detection of airway compromise with pulse oximetry. 4, 11 Given these limitations, a direct assessment of ventilatory status would offer an enhancement over clinical assessment and pulse oximetry.
Currently, the only direct assessment of patient ventilation advocated in PSA practice guidelines is the health care provider's subjective observation of ventilation rate and depth. 1, 10 Our findings suggest the limited utility of this subjective ventilatory assessment, because abnormal ETCO 2 findings were common during many of the PSA encounters. This observation has been previously reported in similar settings. 4, [6] [7] [8] [9] End-tidal carbon dioxide monitoring has been shown to be the earliest indicator of airway compromise. 7, [12] [13] [14] [15] Our study attempted to investigate the quantitative temporal relationship between SpO 2 and ETCO 2 monitoring in the detection of PSA-related acute respiratory events. Changes in ETCO 2 values in response to patient hypoventilation or apnea occurred in the majority of patients before changes in SpO 2 . In cases where acute respiratory events were observed and acted on by the clinical team, blinded abnormal ETCO 2 findings were often present at the time of or up to four minutes before clinical recognition.
Our results support a recent editorial advocating the use of routine ETCO 2 monitoring for deep sedation. 16 ETCO 2 monitoring has not been widely adopted for ED PSA due to the lack of data demonstrating its ability to increase detection of acute respiratory events. 1 Previous investigations have demonstrated transient hypercapnia associated with brief periods of hypoventilation requiring no interventions. 1 In contrast, we observed reduction or absence of ETCO 2 in most cases where an abnormal ETCO 2 finding was recorded. We believe this observation is an accurate representation of ETCO 2 findings in patients with hypoventilation or apnea. No hyperventilation of patients was noted clinically during the investigation, and hyperventilation was not shown in study respiratory rate data to account for the observed low ETCO 2 values during PSA. A balance must exist between a monitoring modality that detects clinically relevant data contributing to patient safety and a monitoring modality that captures ''abnormal findings'' of questionable value to the clinical encounter. While the clinical observation and routine monitoring of patients with respiratory events in this investigation were often preceded by abnormal ETCO 2 findings, many abnormal ETCO 2 events were isolated or transient and not associated with a subsequent clinically meaningful event requiring intervention by the clinical team. Additionally, the impact of earlier detection of hypoventilation and/or apnea with ETCO 2 data does not necessarily translate into the potential to effect a clinical intervention that would have altered the recorded respiratory event. Future studies are needed to investigate the impact of routine ETCO 2 monitoring on reduction of patient acute respiratory events during ED PSA, including hypoxemia and airway interventions.
LIMITATIONS
The acute respiratory event rate observed in our study population was higher than the anticipated pretest projections. The initial projection rate was based on our current PSA database, which may have underrepresented the incidence of acute respiratory events. Alternatively, the elevated acute respiratory event rate observed in the trial may be attributable to a high enrollment of patients with deep sedation encounters or patients deemed to be at higher risk for an acute respiratory event (a sampling bias). Another limitation to our methodology was the data capture technology used during the study. This technology was not enabled to record continuous ETCO 2 data. To offset this concern, we elected to frequently record patient monitoring data at predefined intervals throughout the clinical encounter. The lack of continuous data capture prevented a precise determination of the onset time of patient monitor changes.
CONCLUSIONS
End-tidal carbon dioxide monitoring of patients undergoing PSA detected many clinically significant acute respiratory events before standard ED monitoring practice did so. The majority of acute respiratory events noted in this trial were preceded by ETCO 2 abnormalities that occurred before changes in SpO 2 or observed hypoventilation and apnea.
